ليتروزول تيڤع

Kraj: Izrael

Język: arabski

Źródło: Ministry of Health

Składnik aktywny:

LETROZOLE 2.5 MG

Dostępny od:

TEVA PHARMACEUTICAL INDUST.LTD

Kod ATC:

L02BG04

Forma farmaceutyczna:

TABLETS

Droga podania:

PER OS

Wyprodukowano przez:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupa terapeutyczna:

LETROZOLE

Wskazania:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data autoryzacji:

2010-01-01